This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
In Colombia, Dunkin' Donuts opened its first store in Bogotá in 1983. By 2015, Dunkin' Donuts operated more than 100 stores only in the capital city of the country. As of February 2016, it operates more than 150 stores around the country including locations in the cities of Medellín, Cali, Ibagué, Pereira, Manizales and Barranquilla. In January 2014, Dunkin' Donuts relaunched in England 20 years after it exited the country with its store opening in Harrow, London. There are no Dunkin' Donuts stores in Scotland, Northern Ireland or Wales. On December 5, 2014, Dunkin' Donuts opened their first location in the Nordic region, at the Täby Centrum shopping mall in the outskirts of Stockholm, Sweden. On July 24, 2018, Dunkin' Donuts announced that the company's Swedish operations had filed for bankruptcy and all locations in Sweden would close immediately. On April 1, 2015, the first store in Denmark opened in Copenhagen Central Station and by May 5, 2015, one opened at Roskilde railway station. There is still one under construction in Odense. In early December 2015, Dunkin' Donuts opened their first cafe in 13 years in Warsaw. By 2018, the Polish franchisee, Varsovia Food Company Sp. z o.o., operated five stores across Poland. In August 2018, Dunkin' decided to withdraw from the Polish market, leading the franchisee to terminate its remaining leases. On January 21, 2016, Dunkin' Brands announced a master franchise agreement with Grand Parade Investments Ltd. that called for developing 250 Dunkin' Donuts and 70 Baskin-Robbins outlets throughout South Africa.
The institutions at lower levels were overseen and at times supplanted by primary party organizations. However, in practice the degree of control the party was able to exercise over the state bureaucracy, particularly after the death of Stalin, was far from total, with the bureaucracy pursuing different interests that were at times in conflict with the party, nor was the party itself monolithic from top to bottom, although factions were officially banned.
== International activities == • President of the Association of Schools of Public Health in the European Region (ASPHER) (2011–2013) • Member of the Governing Council of the European Public Health Association (EUPHA); co‑chair and later chair of the Public Health Genomics Section (2015–2021); co‑chair of the Healthy Ageing Section (2023–present) • Co‑chair of the WHO European Advisory Committee on Health Research (2012–2021) • Member of the EU Horizon 2020 Advisory Board (2014–2018) • Member of the Advisory Board of the WHO “Ageing is Living 2026–2030” flagship project (2025–present)
Sources: en.wikipedia.org
== Pharmacokinetics == Tofisopam is also claimed to be a PDE10A inhibitor, which may provide an alternative mechanism of action for its various therapeutic effects, and this action has been proposed to make tofisopam potentially useful as a treatment for schizophrenia. Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.
Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. Its name is derived from poly- 'many', myos- 'muscle' and -itis 'inflammation'. The inflammation of polymyositis is mainly found in the endomysial layer of skeletal muscle, whereas dermatomyositis is characterized primarily by inflammation of the perimysial layer of skeletal muscles.
=== Available forms === Pure lorazepam is an almost white powder that is nearly insoluble in water and oil. In medicinal form, it is mainly available as tablets and a solution for injection, but, in some locations, it is also available as a skin patch, an oral solution, and a sublingual tablet. Lorazepam injectable solution is administered either by deep intramuscular injection or by intravenous injection. The injectable solution comes in 1 mL ampoules containing 2 or 4 mg of lorazepam. The solvents used are polyethylene glycol 400 and propylene glycol. As a preservative, the injectable solution contains benzyl alcohol. Toxicity from propylene glycol has been reported in the case of a person receiving a continuous lorazepam infusion. Topical formulations of lorazepam, while sometimes used as a treatment for nausea, especially in people in hospice, has been advised against by the American Academy of Hospice and Palliative Medicine for this purpose as it has not been proven effective.
Sources: en.wikipedia.org
At about T+5 minutes was SECO (Sustainer Engine Cutoff) and Faith 7 entered orbit at 17,547 mph (7,844 m/s). After the spacecraft separated and turned around to orbit attitude, Cooper watched the spent Atlas lag behind and tumble for about eight minutes. Over Zanzibar on the first orbit, he learned that the orbital parameters were good enough for at least 20 orbits. As the spacecraft passed over Guaymas, Mexico still on the first orbit, capsule communicator Gus Grissom told Cooper the ground computers said he was "go for seven orbits." Atlas performance was overall excellent. The upgraded propulsion system worked well, with slightly above nominal booster engine thrust. Measurable propellant slosh occurred from T+55 to T+120 seconds, caused by slightly lower than nominal autopilot gains. The flight trajectory was slightly more lofted than nominal due to the DC voltage in the booster electrical system being about 0.7 volts above normal, but this was counteracted by the higher than nominal booster engine performance. BECO took place at T+132 seconds, escape tower jettison at T+141 seconds, and SECO at T+303 seconds.
dyspepsia of a non-ulcer/dysmotility type (gastric "fullness", discomfort, and possible pain) gastroparesis (delayed gastric emptying) anorexia heartburn regurgitation bloating nausea and vomiting other possible gastric, prolactin, or dopamine related conditions Itopride was shown to significantly improve symptoms in patients with functional dyspepsia and motility disorders in placebo-controlled trials. These studies concluded that the reduction in the severity of symptoms of functional dyspepsia after 8 weeks of treatment with itopride indicated that itopride was significantly superior to placebo and that itopride yielded a greater rate of response than placebo in significantly reducing pain and fullness.
== Further reading == Author I'm Not the Only One (2004) Mr Galloway Goes to Washington (2005) Fidel Castro Handbook (2006), MQ Publications. ISBN 1-84072-688-1 Respect: Documents of the Crisis (2008) with Salma Yaqoob and Alan Thornett Open Season: The Neil Lennon Story (2011) Miranda Media
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.